Coronary Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Coronary Disease Global Clinical Trials Review, H1, 2012" provides data on the Coronary Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acute Lung Injury Global Clinical Trials Review, H2, 2012ReportLinker.com
Acute Lung Injury Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Acute Lung Injury Global Clinical Trials Review, H2, 2012" provides data on the Acute Lung Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Lung Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Lung Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Congenital Heart Disease Global Clinical Trials Review, H1, 2012ReportLinker.com
Congenital Heart Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Congenital Heart Disease Global Clinical Trials Review, H1, 2012" provides data on the Congenital Heart Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Congenital Heart Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Congenital Heart Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Liver Fibrosis Global Clinical Trials Review, H1, 2013ReportLinker.com
Liver Fibrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Liver Fibrosis Global Clinical Trials Review, H1, 2013" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Fibrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on clinical trials for left ventricular dysfunction from 2012. It includes statistics on 97 clinical trials by region, country, phase, sponsor, and drug. The report gives an overview of trial recruitment status and numbers globally, and lists the top contributing countries, sponsors, and universities to left ventricular dysfunction trials in 2012.
Acute Lung Injury Global Clinical Trials Review, H2, 2012ReportLinker.com
Acute Lung Injury Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Acute Lung Injury Global Clinical Trials Review, H2, 2012" provides data on the Acute Lung Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Lung Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Lung Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Cancer Cachexia Global Clinical Trials Review, H1, 2013ReportLinker.com
Cancer Cachexia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Cancer Cachexia Global Clinical Trials Review, H1, 2013" provides data on the Cancer Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Cachexia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Congenital Heart Disease Global Clinical Trials Review, H1, 2012ReportLinker.com
Congenital Heart Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Congenital Heart Disease Global Clinical Trials Review, H1, 2012" provides data on the Congenital Heart Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Congenital Heart Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Congenital Heart Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Liver Fibrosis Global Clinical Trials Review, H1, 2013ReportLinker.com
Liver Fibrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Liver Fibrosis Global Clinical Trials Review, H1, 2013" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Fibrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on clinical trials for left ventricular dysfunction from 2012. It includes statistics on 97 clinical trials by region, country, phase, sponsor, and drug. The report gives an overview of trial recruitment status and numbers globally, and lists the top contributing countries, sponsors, and universities to left ventricular dysfunction trials in 2012.
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Investigated the market for cardiovascular medical devices and clinical research organizations (CROs) to understand what roles play in the development and FDA approval process for therapeutics.
CHIR Best Brains Exchange 22 January 2016Ajaz Hussain
Quality of drugs manufactured in emerging economies: Are cost containment strategies heightening the likelihood of substandard drugs in Canada?
What regulatory, policy, and/ or governance changes are needed to address new and increased risks?
How can Canada prevent and reduce health risks that emerge when the pharmaceutical industry adopts globalized production strategies?
The document discusses the evolving pharmaceutical industry model and whether it is "fit for purpose or broken". It summarizes that while R&D costs per new drug are rising and productivity seems to be falling, the industry model is not truly broken but rather changing in response to challenges. Key changes include R&D shifting to diseases important to payers, industry consolidation, and adaptive pathways being developed between industry, payers, and regulators for patient access and evidence collection. While affordability issues arise from both a potentially broken model and successful adaptation, both high returns on R&D and reasonable drug prices must be addressed to sustain innovation.
Uveitis global clinical trials review, h1, 2015Ambikabasa
Product Synopsis
Uveitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, Uveitis Global Clinical Trials Review, H1, 2015" provides an overview of Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database - Pharma eTrack Clinical trials database.
http://www.researchmoz.us/uveitis-global-clinical-trials-review-h1-2015-report.html
This document summarizes a presentation on strategies for boosting pharmaceutical innovation given by Kenneth Kaitin. It discusses the current challenging environment for drug development, including expiring patents, competitive markets, and high costs. Drug development times are long with low success rates, driving costs upwards. Oncology has become a major focus of R&D investment. The presentation proposes ways to stimulate innovation in areas of high medical need but low commercial appeal, such as through regulatory and legislative incentives.
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketMarketResearch.com
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years. Contract Research Organizations (CROs) and other entities can expect growing demand for their services.
The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information's Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
The document summarizes key happenings and trends from the 2014 AACC annual meeting and clinical lab expo in Chicago. Specifically:
- Point of care and infectious disease testing were highlighted areas with over 20% of exhibitors.
- Emerging "grassroots molecular" point of care systems were showcased, including systems from Cepheid, Quidel, Nanosphere, and others aiming to provide sample to result testing outside central labs.
- Animal diagnostics and emerging metabolomics offerings were other notable areas exhibited by some companies seeking new opportunities beyond traditional human diagnostics.
Argus Patient Screen Tab Training - Katalyst HLSKatalyst HLS
This document provides instructions for entering patient information, medical history, and laboratory data into the ARGUS patient screening system. It describes how to enter initials only for patient name, date of birth using hyphens for missing parts, and age manually if date of birth is partial. Relevant medical history, including conditions, historical drugs, and family history should be included. Laboratory results should be entered in the coded field if abnormal and relevant to events, and normal tests or those not codable go in the free text field. Dates and details like units should be included.
Finding the right medical device information in embase 11 2016Ann-Marie Roche
The document discusses guidelines for systematic reviews of biomedical literature in Clinical Evaluation Reports (CERs) for medical devices, highlighting how Embase addresses the requirements through its comprehensive indexing of devices, manufacturers, and adverse effects, as well as features for building sensitive searches. It also provides examples of searches in Embase to find information on device clinical performance, comparisons, and safety for a case study on an everolimus eluting coronary stent.
Healthcare Contract Research Organization (CRO) MarketTom Clark
Global Healthcare Contract Research Organization (CRO) Market is expected to reach USD 51.3 billion by 2024 with CAGR of 6.5% over the future period as the scope and its applications are rising enormously across the globe.
Survival guide to stem cell research and therapiesArete-Zoe, LLC
Survival guide to stem cell research and therapies provides comprehensive guidance to publicly available resource materials, libraries and registries for people who are interested in understanding currently available treatment options involving human stem cells.
Potential: The first section explains how stem cells are currently used in research, drug testing, and therapy, and how they have to be manipulated before transfer to make any treatments possible.
Classification: Origin and ability of stem cells to differentiate into different cell types determine how different types of stem cells are typically used.
Clinical Research: In this section, we will introduce the two most important registries of clinical trials: NIH registry ClinicalTrials gov and WHO International Clinical Trials Registry Platform. A project is part of this section to give students the opportunity to get hands-on experience with collecting and collating relevant information from registries and libraries, and interpretation of the findings. Real-time interactive sessions are included to allow students to ask questions and offer additional guidance.
Patient Demand: In this section, we briefly introduce challenges relating to marketing claims, objective outcome measures, advertising strategies, and patient autonomy.
Regulatory and Legal Framework: Stem cell therapies are regulated differently in various countries around the world. In this section, we will focus on regulations that govern stem cell research and therapies in the U.S. and in the European Union. Policies on stem cell research are driven by ethical concerns relating to research that utilizes human embryos. China recently announced new ethical guidelines and new rules for its stem cell clinics, regulating both trials and treatments.
Professional Societies: The last section explains the role of professional societies in stem cell research and therapies.
Embase for pharmacovigilance: Search and validation March 22 2017Ann-Marie Roche
Scientific literature plays a critical role in Pharmacovigilance and Drug Safety workflows. Monitoring literature for mentions of adverse drug reactions (ADRs) is mandated by regulatory bodies, and marketing authorization holders (MAHs) that do not properly report ADRs can be subject to heavy fines. With an increasing volume of unstructured content to cover, along with rising labor costs, MAHs are looking for ways to make their literature monitoring more effective and efficient.
Abstract and indexing (A&I) databases play an important role in Literature Monitoring – due to the vast amount of scientific literature published daily – in order for MAH’s to locate specific articles or conference presentations that may be relevant for their products (for both benefit/risk analysis and ADR detection). Rather than reading all the literature, MAH’s create search strategies that identify the relevant records in A&I databases and execute the searches regularly. GVP module VI mandates that searches are done at least weekly, but many companies maintain a daily monitoring and review cycle.
In this webinar, Senior Product Development Manager Embase, Dr. Ivan Krstic discussed best practices for saving time, staying current, validating search strategies and mitigating risk in the face of these increasingly complex processes in literature monitoring
This document discusses redesigning post-market drug safety surveillance. It proposes developing an integrated commercial off-the-shelf post-market surveillance platform to analyze real-world data on prescribing, patient outcomes, and adverse events in a standardized way. This could provide valuable insight into drug safety and efficacy using real-world evidence from clinical practice settings. Currently, post-market surveillance relies on voluntary reporting which results in underreporting and limited data for analyzing trends. The proposed platform aims to address these limitations through consistent analysis of real-world data sources.
Anal Fissure Global Clinical Trials Review, H1, 2013ReportLinker.com
Anal Fissure Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Anal Fissure Global Clinical Trials Review, H1, 2013" provides data on the Anal Fissure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fissure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Pompe Disease Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Pompe disease from January 2013. It provides an overview of the number and location of trials worldwide in the first half of 2013. The US, Germany, and China had the most trials. The trials were mostly in late phases and investigated drugs from companies like Genzyme and Sanofi. The report analyzed trial trends over time and provided profiles of top trial sponsors.
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
New technologies and the outsourcing of clinical trials to lower-cost countries will slow the recent annual increases in expenditures in the U.S. to a 3.3% compound annual growth rate (CAGR) over the forecast period.
Investigated the market for cardiovascular medical devices and clinical research organizations (CROs) to understand what roles play in the development and FDA approval process for therapeutics.
CHIR Best Brains Exchange 22 January 2016Ajaz Hussain
Quality of drugs manufactured in emerging economies: Are cost containment strategies heightening the likelihood of substandard drugs in Canada?
What regulatory, policy, and/ or governance changes are needed to address new and increased risks?
How can Canada prevent and reduce health risks that emerge when the pharmaceutical industry adopts globalized production strategies?
The document discusses the evolving pharmaceutical industry model and whether it is "fit for purpose or broken". It summarizes that while R&D costs per new drug are rising and productivity seems to be falling, the industry model is not truly broken but rather changing in response to challenges. Key changes include R&D shifting to diseases important to payers, industry consolidation, and adaptive pathways being developed between industry, payers, and regulators for patient access and evidence collection. While affordability issues arise from both a potentially broken model and successful adaptation, both high returns on R&D and reasonable drug prices must be addressed to sustain innovation.
Uveitis global clinical trials review, h1, 2015Ambikabasa
Product Synopsis
Uveitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, Uveitis Global Clinical Trials Review, H1, 2015" provides an overview of Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database - Pharma eTrack Clinical trials database.
http://www.researchmoz.us/uveitis-global-clinical-trials-review-h1-2015-report.html
This document summarizes a presentation on strategies for boosting pharmaceutical innovation given by Kenneth Kaitin. It discusses the current challenging environment for drug development, including expiring patents, competitive markets, and high costs. Drug development times are long with low success rates, driving costs upwards. Oncology has become a major focus of R&D investment. The presentation proposes ways to stimulate innovation in areas of high medical need but low commercial appeal, such as through regulatory and legislative incentives.
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketMarketResearch.com
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years. Contract Research Organizations (CROs) and other entities can expect growing demand for their services.
The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information's Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
The document summarizes key happenings and trends from the 2014 AACC annual meeting and clinical lab expo in Chicago. Specifically:
- Point of care and infectious disease testing were highlighted areas with over 20% of exhibitors.
- Emerging "grassroots molecular" point of care systems were showcased, including systems from Cepheid, Quidel, Nanosphere, and others aiming to provide sample to result testing outside central labs.
- Animal diagnostics and emerging metabolomics offerings were other notable areas exhibited by some companies seeking new opportunities beyond traditional human diagnostics.
Argus Patient Screen Tab Training - Katalyst HLSKatalyst HLS
This document provides instructions for entering patient information, medical history, and laboratory data into the ARGUS patient screening system. It describes how to enter initials only for patient name, date of birth using hyphens for missing parts, and age manually if date of birth is partial. Relevant medical history, including conditions, historical drugs, and family history should be included. Laboratory results should be entered in the coded field if abnormal and relevant to events, and normal tests or those not codable go in the free text field. Dates and details like units should be included.
Finding the right medical device information in embase 11 2016Ann-Marie Roche
The document discusses guidelines for systematic reviews of biomedical literature in Clinical Evaluation Reports (CERs) for medical devices, highlighting how Embase addresses the requirements through its comprehensive indexing of devices, manufacturers, and adverse effects, as well as features for building sensitive searches. It also provides examples of searches in Embase to find information on device clinical performance, comparisons, and safety for a case study on an everolimus eluting coronary stent.
Healthcare Contract Research Organization (CRO) MarketTom Clark
Global Healthcare Contract Research Organization (CRO) Market is expected to reach USD 51.3 billion by 2024 with CAGR of 6.5% over the future period as the scope and its applications are rising enormously across the globe.
Survival guide to stem cell research and therapiesArete-Zoe, LLC
Survival guide to stem cell research and therapies provides comprehensive guidance to publicly available resource materials, libraries and registries for people who are interested in understanding currently available treatment options involving human stem cells.
Potential: The first section explains how stem cells are currently used in research, drug testing, and therapy, and how they have to be manipulated before transfer to make any treatments possible.
Classification: Origin and ability of stem cells to differentiate into different cell types determine how different types of stem cells are typically used.
Clinical Research: In this section, we will introduce the two most important registries of clinical trials: NIH registry ClinicalTrials gov and WHO International Clinical Trials Registry Platform. A project is part of this section to give students the opportunity to get hands-on experience with collecting and collating relevant information from registries and libraries, and interpretation of the findings. Real-time interactive sessions are included to allow students to ask questions and offer additional guidance.
Patient Demand: In this section, we briefly introduce challenges relating to marketing claims, objective outcome measures, advertising strategies, and patient autonomy.
Regulatory and Legal Framework: Stem cell therapies are regulated differently in various countries around the world. In this section, we will focus on regulations that govern stem cell research and therapies in the U.S. and in the European Union. Policies on stem cell research are driven by ethical concerns relating to research that utilizes human embryos. China recently announced new ethical guidelines and new rules for its stem cell clinics, regulating both trials and treatments.
Professional Societies: The last section explains the role of professional societies in stem cell research and therapies.
Embase for pharmacovigilance: Search and validation March 22 2017Ann-Marie Roche
Scientific literature plays a critical role in Pharmacovigilance and Drug Safety workflows. Monitoring literature for mentions of adverse drug reactions (ADRs) is mandated by regulatory bodies, and marketing authorization holders (MAHs) that do not properly report ADRs can be subject to heavy fines. With an increasing volume of unstructured content to cover, along with rising labor costs, MAHs are looking for ways to make their literature monitoring more effective and efficient.
Abstract and indexing (A&I) databases play an important role in Literature Monitoring – due to the vast amount of scientific literature published daily – in order for MAH’s to locate specific articles or conference presentations that may be relevant for their products (for both benefit/risk analysis and ADR detection). Rather than reading all the literature, MAH’s create search strategies that identify the relevant records in A&I databases and execute the searches regularly. GVP module VI mandates that searches are done at least weekly, but many companies maintain a daily monitoring and review cycle.
In this webinar, Senior Product Development Manager Embase, Dr. Ivan Krstic discussed best practices for saving time, staying current, validating search strategies and mitigating risk in the face of these increasingly complex processes in literature monitoring
This document discusses redesigning post-market drug safety surveillance. It proposes developing an integrated commercial off-the-shelf post-market surveillance platform to analyze real-world data on prescribing, patient outcomes, and adverse events in a standardized way. This could provide valuable insight into drug safety and efficacy using real-world evidence from clinical practice settings. Currently, post-market surveillance relies on voluntary reporting which results in underreporting and limited data for analyzing trends. The proposed platform aims to address these limitations through consistent analysis of real-world data sources.
Anal Fissure Global Clinical Trials Review, H1, 2013ReportLinker.com
Anal Fissure Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Anal Fissure Global Clinical Trials Review, H1, 2013" provides data on the Anal Fissure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anal Fissure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anal Fissure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Inguinal Hernia Global Clinical Trials Review, H1, 2013ReportLinker.com
Inguinal Hernia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Inguinal Hernia Global Clinical Trials Review, H1, 2013" provides data on the Inguinal Hernia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inguinal Hernia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inguinal Hernia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Abdominal Aortic Aneurysms Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report from GlobalData on clinical trials for abdominal aortic aneurysms. The report provides data on over 100 clinical trials conducted between 2007-2012, including regional breakdown of trials, top sponsoring companies and universities, prominent drugs being tested, and trends in trial enrollment numbers over time. The report aims to give readers an overview of experimental treatments and global research activity for abdominal aortic aneurysms.
Sezary Syndrome Global Clinical Trials Review, H1, 2013ReportLinker.com
This document summarizes a report on clinical trials for Sezary Syndrome from January 2013. It provides an overview of the number and location of trials worldwide. The report details trials by region, country, phase, status, subjects recruited, and prominent sponsors. It also profiles the top companies and universities/institutes conducting Sezary Syndrome trials.
Asperger Syndrome Global Clinical Trials Review, H2, 2012ReportLinker.com
Asperger Syndrome Global Clinical Trials Review, H2, 2012
Summary
GlobalData's clinical trial report, 'Asperger Syndrome Global Clinical Trials Review, H2, 2012" provides data on the Asperger Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Asperger Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Asperger Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Endometrial Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a 107-page report on endometrial cancer clinical trials in the second half of 2012. It details the number of clinical trials conducted by region, country, phase, status, subjects recruited, and leading sponsors. The report aims to give an overview of the global clinical trial landscape for endometrial cancer and benchmark trial activity and trends over time. It is available for individual purchase at a price of $2,500.
Gastric Cancer Global Clinical Trials Review, H2, 2012ReportsnReports
The document provides a summary of a report on gastric cancer clinical trials in the second half of 2012. It includes 123 pages of data on over 1,000 clinical trials conducted globally, including information on the number and location of trials, participating companies and institutions, trial status and recruitment numbers. The report is available for purchase for $2,500 and provides detailed insight into ongoing and discontinued gastric cancer trials worldwide.
Filariasis Global Clinical Trials Review, H1, 2013ReportLinker.com
Filariasis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Filariasis Global Clinical Trials Review, H1, 2013" provides data on the Filariasis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Filariasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Filariasis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H2, 2012ReportsnReports
This document provides a 139-page report on global clinical trials for kidney cancer (renal cell cancer) in the second half of 2012. It includes data on the number and location of clinical trials, breakdown of trials by phase, status, subject recruitment, and leading sponsors. The report aims to give an overview of the clinical trial landscape and assess trends in research and development for treating kidney cancer worldwide.
The document provides an overview and analysis of clinical trials being conducted for ulcers on a global level in the first half of 2014. It summarizes the number of trials by region, with the most trials occurring in Asia-Pacific and Europe. The report also outlines the top countries contributing trials for each region and details clinical trials by phase, status, sponsor type, and recruited subjects over time. It concludes with profiles of prominent companies and institutions conducting ulcer trials.
This report presents a comprehensive analysis of the US blood banking market, including:Major issues pertaining to the US blood banking practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Specifically, the study explores the impact of anticipated changes in government regulations, trends in complicated surgeries, birth rate and other key issues.Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in US community and regional blood centers, hospitals, commercial laboratories, and plasma fractionation facilities.Annual placements and installed base estimates for major automated and semiautomated analyzers. Review of current instrumentation technologies, and a feature comparison of over 20 analyzers. Ten-year reagent and instrument sales forecasts.Sales and market shares of leading reagent and instrument suppliers.Review of current and emerging technologies, and their potential market applications.Product development opportunities for instruments ,consumables, and auxiliary products.Profiles of major current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.Business opportunities and strategic recommendations for suppliers.Contains 460 pages and 53 tables
There are an estimated 33.3 million people living with HIV (the virus which causes AIDS) worldwide and approximately 2.6 million people are newly-infected each year. While the Asian and African regions account for more than 90% of the HIV-infected population (with the highest number in Sub-Saharan Africa), the U.S. and European regions make up greater than 60% of the HIV testing market. This TriMark Publications report provides a comprehensive examination of the HIV/AIDS testing market, a specific segment of the in vitro diagnostics (IVD) market as it relates to infectious diseases. It examines the available and emerging technologies being utilized by the HIV testing field, defines the dollar volume of sales'both in the U.S. and worldwide'and analyzes the factors that influence the size and growth of the market. The chief HIV testing assays, i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic, are covered thoroughly, as are high-growth applications in different clinical diagnostic areas and expanding markets, such as employee screening, emergency medicine and satellite clinic testing. Additionally, this analysis covers the following areas in details: enzyme-linked immunosorbent assay (ELISA), antibody/p24 antigen test (fourth-generation test), Western blot assay, line immunoassays, indirect fluorescent antibody (IFA) assay, nucleic acid tests for infectious diseases, and the emerging technologies related to HIV and AIDS diagnosis. Moreover, this study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing HIV testing products, as well as provides detailed tables and figures covering HIV testing markets around the globe.
The document discusses the process and costs associated with drug development. It notes that the average cost to develop a new drug is $350 million to $5.5 billion and the process takes 6.5-7 years from discovery to approval. Key barriers to drug development include high financial costs, lengthy timelines for clinical trials, and regulatory hurdles. Approaches to reduce costs and timelines include greater use of electronic health records, simplifying clinical trial protocols, and utilizing decentralized clinical trial models.
This document provides a summary of the Oncology Drug Report 2014, which is described as the world's largest active resource for decision making in oncology. Some key details include:
- It covers 931 active cancer drug developers across 33 countries, along with profiles of 2237 active drugs in development, 37 cancer indications under pipeline analysis, and 523 clinical and 360 preclinical and discovery companies.
- The report is organized across 6 sections and provides comprehensive intelligence on the global oncology drug development landscape, including clinical trials, targets, mechanisms of action, deals and partnerships for individual drugs and companies.
- It aims to help businesses, scientists, investors and clinicians make better decisions by bringing extensive data together in one place
This document provides a summary of a comprehensive oncology intelligence report for 2013. The report contains over 800 pages divided into 6 sections with infographics and tables. It covers aspects of cancer drug development including companies, clinical trials, targets, indications and molecules in development. The report is designed to provide up-to-date intelligence on competition, collaboration patterns, emerging targets and research trends to help with strategic decision making. Each section analyzes the data through infographics and profiles of over 400 cancer-focused companies to explore research trends, development strategies and changes in the oncology landscape over time.
Global Uro-Gynecological Surgical Devices IndustryReportLinker.com
This report analyzes the worldwide markets for Uro-Gynecological Surgical Devices in US$ Million by the following segments: Urological Surgical Devices (Sling & Suspension Devices, & Other Urological Devices), and Gynecological Surgical Devices (Endometrial Ablation Devices, Endoscopes, Hysteroscope Systems, Fluid Management Systems, & Other Gynecological Devices). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia'Pacific, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 66 companies including many key and niche players such as Gyrus ACMI Corporation, American Medical Systems Holdings Incorporated, Boston Scientific Corporation, C. R. Bard, Inc., Cook Urological Inc., CooperSurgical, Inc., Hologic Inc., Ethicon, Inc., Cytyc Corporation, Cytyc Surgical Products, Ethicon Inc., Karl Storz GmbH & Co. KG, MDMI Technologies, Inc., Medtronic, Inc., Olympus America Inc., Olympus Surgical & Industrial America, Inc., Richard Wolf GmbH, and Stryker Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
This document summarizes a report on cardiac toxicity. Cardiac toxicity, where drugs cause heart damage, has led to 28% of drug withdrawals over the last 30 years in the US. If cardiac toxicity is found during drug development or after launch, it can terminate development programs or require drugs to be withdrawn from the market. The report covers the physiology, pharmacology, clinical testing, regulation, and commercial implications of cardiac toxicity. It is intended to help understand, manage, and plan for the risks of cardiac toxicity.
The document provides an overview of the global liquid biopsy market forecast from 2020 to 2025. It discusses key aspects of the market such as application, end user, clinical application, product/service, circulating biomarker, technology, and region. It also profiles major companies in the market and their recent developments. The global liquid biopsy market is expected to grow significantly due to the rising adoption of non-invasive cancer screening and monitoring techniques. However, lack of standardization and low reimbursement rates may hinder the market growth.
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
This document summarizes a presentation given by Dr. Robert Boorstein on drivers of change in the laboratory market. Five key trends are discussed: laboratory consolidation, growth of central laboratories vs point-of-care testing, new delivery models, new technologies, and increased competition across sectors. Laboratory consolidation is driven by cost reductions and allows for standardization but may shift market power from sellers to buyers. Point-of-care testing is growing rapidly but poses challenges to quality control. New national laboratory companies are emerging focused on unique branded products.
Similar to Coronary Disease Global Clinical Trials Review, H1, 2012 (20)
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
Interview Co-Founder ReportLinker and Findout, Benjamin CarpanoReportLinker.com
ReportLinker and Findout use data analytics technologies to aggregate and normalize data from a wide range of sources to help researchers and analysts find relevant information more efficiently. The companies' core competency lies in both search and data analytics capabilities. Their natural language processing platform analyzes millions of documents daily to extract and structure concepts, relationships, and sentiments to improve users' productivity. Open data initiatives have helped the businesses by providing more content to incorporate, though most value comes from backend processing rather than raw data access. The companies aim to continue enhancing data discovery and contextualization of results.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
This document provides a summary of a report on the European branded coffee shop market in 23 countries. Some key points:
- It examines the size and growth of the branded coffee shop market in each country from 2009-2015. Several countries like Poland and Spain saw strong growth over 10% in 2011-2012.
- Market leaders like Starbucks, Costa Coffee and Coffee Fellows are profiled for each country along with operating statistics and strategies. Consumer trends toward convenience and sustainability are also discussed.
- Challenges facing the industry like economic uncertainty and high rents are analyzed. Success factors include quality coffee, food offerings and a strong brand. The growth potential of each market is evaluated based on GDP per capita and existing
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
This document is a fax order form for reports from ReportLinker, which provides industry reports, company profiles, and market statistics. It contains fields for customers to provide contact and billing information as well as select a payment method of credit card, wire transfer, or check in order to place an order for reports. The form directs customers to fax the completed form back to ReportLinker offices in either Europe, the Middle East, and Africa or Asia, Oceania, and America depending on location.
This document is a fax order form for industry reports and company profiles from ReportLinker. It contains fields for customers to provide their contact and shipping information as well as payment details including credit card number, expiration date, and CVV. The form also lists ReportLinker's fax numbers for customers in different regions to submit their orders.
This very short document contains a single word - "TEST" - with no other context provided. It is not possible to provide a meaningful summary in 3 sentences or less given the extremely limited information.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This document provides a summary and table of contents for a 900-page report analyzing the clinical chemistry and immunodiagnostic markets in five major European countries. The report explores trends, evaluates competitors, and identifies opportunities in these evolving markets. It contains estimates of test volumes, sales forecasts by category and country, and competitive profiles of leading suppliers.
This document is a report on the China iron ore mining industry in 2013. It provides an overview of the industry, including its definition and development history. It analyzes the macroeconomic environment and discusses factors like policy, upstream/downstream industries. It also examines the international and domestic markets. Key data on the industry from 2008-2012 is presented, including numbers of enterprises, employees, assets, output, sales, profits and trade. The competitive landscape and strategies of major companies are evaluated. The report concludes with discussions of development trends, investment environment and new technologies in the industry.
This document provides a summary and table of contents of the "World Biomass Report" published in November 2012. The report examines the global biomass market and finds that while it suffered during the economic downturn due to low coal prices and supply issues, the sector began growing again in 2010 as coal prices rose. Most biomass plants rely on wood pellets imported from North America, though suppliers from other regions like Russia and Australia aim to compete in the market. The full report contains detailed information on biomass resources, technologies, logistics, investments and policies on a global and national level.
This report provides an overview of the global biofuels industry in 2012. It summarizes production and policies related to first, second, and third generation biofuels in countries around the world. The report finds that 2009 was a difficult year for the biofuels industry due to low oil prices and reduced demand. However, projects using diverse feedstocks or next generation technologies like cellulosics and algae continued to receive investment. The report includes sections on biofuel production trends, technologies, environmental impacts, and policies in regions like Europe, the USA, and individual European countries.
This report analyzes the current state of various renewable energy technologies including hydropower, wind, solar, biomass, biofuels, and geothermal. It examines the market size and outlook for each technology by region, discusses the advantages and disadvantages of different renewable sources, and assesses the development status and future potential of the renewable energy industry globally. The report also profiles major renewable energy companies and evaluates government policies and industry support programs around the world.
This report provides an overview of the global solar photovoltaic (PV) market. It outlines key industry data like global solar capacity, production figures, and forecasts for future growth. It also examines major country markets and discusses the advantages, challenges, and components of the solar PV industry. The report analyzes factors such as government incentives, technology developments, and manufacturing trends that are shaping the future of the solar industry.
Coronary Disease Global Clinical Trials Review, H1, 2012
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Coronary Disease Global Clinical Trials Review, H1, 2012
Published on June 2012
Report Summary
Coronary Disease Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, 'Coronary Disease Global Clinical Trials Review, H1, 2012" provides data on the Coronary Disease
clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Disease. It includes
an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a
preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing
pertaining to the number of trials for the key drugs for treating Coronary Disease. This report is built using data and information
sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and
Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Content
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Coronary Disease 7
Report Guidance 7
Clinical Trials by Region 8
Coronary Disease Global Clinical Trials Review, H1, 2012 (From Slideshare) Page 1/8
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Clinical Trials by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by BRIC Nations 16
Clinical Trials by G7 Nations 17
Clinical Trials in G7 Nations by Trial Status 18
Clinical Trials by E7 Nations 19
Clinical Trials in E7 Nations by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Unaccomplished Trials of Coronary Disease 24
Subjects Recruited Over a Period of Time 29
Prominent Sponsors 30
Top Companies Participating in Coronary Disease Therapeutics Clinical Trials 32
Prominent Drug Comparison 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Merck & Co., Inc. 35
Clinical Trial Overview of Merck & Co., Inc. 35
AstraZeneca PLC 37
Clinical Trial Overview of AstraZeneca PLC 37
Abbott Laboratories 39
Clinical Trial Overview of Abbott Laboratories 39
F. Hoffmann-La Roche Ltd. 40
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 40
GlaxoSmithKline plc 41
Clinical Trial Overview of GlaxoSmithKline plc 41
Pfizer Inc. 42
Clinical Trial Overview of Pfizer Inc. 42
GE Healthcare 43
Clinical Trial Overview of GE Healthcare 43
Genzyme Corporation 44
Clinical Trial Overview of Genzyme Corporation 44
Novartis AG 45
Clinical Trial Overview of Novartis AG 45
TCA Cellular Therapy, LLC 46
Clinical Trial Overview of TCA Cellular Therapy, LLC 46
Clinical Trial Overview of 47
Sanofi 47
Clinical Trial Overview of Sanofi 47
Gilead Sciences, Inc. 48
Clinical Trial Overview of Gilead Sciences, Inc. 48
Acusphere, Inc. 49
Clinical Trial Overview of Acusphere, Inc. 49
Coronary Disease Global Clinical Trials Review, H1, 2012 (From Slideshare) Page 2/8
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
The Medicines Company 50
Clinical Trial Overview of The Medicines Company 50
Scios Inc. 51
Clinical Trial Overview of Scios Inc. 51
AVI BioPharma Inc. 52
Clinical Trial Overview of AVI BioPharma Inc. 52
CardioDx, Inc. 53
Clinical Trial Overview of CardioDx, Inc. 53
Resverlogix Corp. 54
Clinical Trial Overview of Resverlogix Corp. 54
Eisai Inc. 55
Clinical Trial Overview of Eisai Inc. 55
Clinical Trial Overview of Top Universities / Institutes / Hospitals 56
Deutsches Herzzentrum Munchen 56
Clinical Trial Overview of Deutsches Herzzentrum Munchen 56
University of California, San Francisco 57
Clinical Trial Overview of University of California, San Francisco 57
University of Ottawa Heart Institute 58
Clinical Trial Overview of University of Ottawa Heart Institute 58
The University of Edinburgh 59
Clinical Trial Overview of The University of Edinburgh 59
Seoul National University Hospital 60
Clinical Trial Overview of Seoul National University Hospital 60
William Beaumont Hospitals 61
Clinical Trial Overview of William Beaumont Hospitals 61
Brigham and Women's Hospital 62
Clinical Trial Overview of Brigham and Women's Hospital 62
University of Leipzig 63
Clinical Trial Overview of University of Leipzig 63
Assistance Publique - Hopitaux de Paris 64
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 64
Sheba Medical Center 65
Clinical Trial Overview of Sheba Medical Center 65
University of Nebraska 66
Clinical Trial Overview of University of Nebraska 66
Boston University 67
Clinical Trial Overview of Boston University 67
Vanderbilt University 68
Clinical Trial Overview of Vanderbilt University 68
University of Florida 69
Clinical Trial Overview of University of Florida 69
Rigshospitalet 70
Clinical Trial Overview of Rigshospitalet 70
Cedars-Sinai Medical Center 71
Clinical Trial Overview of Cedars-Sinai Medical Center 71
University of Oxford 72
Clinical Trial Overview of University of Oxford 72
Emory University 73
Coronary Disease Global Clinical Trials Review, H1, 2012 (From Slideshare) Page 3/8
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Clinical Trial Overview of Emory University 73
Medical University of Vienna 74
Clinical Trial Overview of Medical University of Vienna 74
Skejby Hospital 75
Clinical Trial Overview of Skejby Hospital 75
Five Key Clinical Profiles 76
Appendix 99
Abbreviations 99
Definitions 100
Research Methodology 101
Secondary Research 101
About GlobalData 102
Contact Us 102
Disclaimer 102
Source 102
List of Tables
Coronary Disease Therapeutics Market, Global, Clinical Trials by Zone, 2012* 8
Coronary Disease Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 9
Coronary Disease Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 10
Coronary Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2012* 11
Coronary Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2012* 12
Coronary Disease Therapeutics Clinical Trials, North America, Top Countries, 2012* 13
Coronary Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2012* 14
Coronary Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2012* 15
Coronary Disease Therapeutics Clinical Trials, BRIC Countries, 2012* 16
Coronary Disease Therapeutics Clinical Trials, G7 Countries, 2012* 17
Coronary Disease Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 18
Coronary Disease Therapeutics Clinical Trials, E7 Countries, 2012* 19
Coronary Disease Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 20
Coronary Disease Therapeutics Market, Global, Clinical Trials by Phase, 2012* 21
Coronary Disease Therapeutics Market, Global, Clinical Trials In Progress by Phase 2012* 22
Coronary Disease Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 23
Coronary Disease Therapeutics Market, Global, Suspended Clinical Trials, 2012* 24
Coronary Disease Therapeutics Market, Global, Withdrawn Clinical Trials, 2012* 25
Coronary Disease Therapeutics Market, Global, Terminated Clinical Trials, 2012* 26
Coronary Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2006-2011 29
Coronary Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 31
Coronary Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 33
Coronary Disease Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 34
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2012* 35
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2012* 37
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2012* 39
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2012* 40
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2012* 41
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2012* 42
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by GE Healthcare, 2012* 43
Coronary Disease Global Clinical Trials Review, H1, 2012 (From Slideshare) Page 4/8
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Genzyme Corporation, 2012* 44
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2012* 45
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by TCA Cellular Therapy, LLC, 2012* 46
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2012* 47
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Gilead Sciences, Inc., 2012* 48
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Acusphere, Inc., 2012* 49
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by The Medicines Company, 2012* 50
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Scios Inc., 2012* 51
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by AVI BioPharma Inc., 2012* 52
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by CardioDx, Inc., 2012* 53
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Resverlogix Corp., 2012* 54
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Inc., 2012* 55
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Deutsches Herzzentrum Munchen, 2012* 56
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2012* 57
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Ottawa Heart Institute, 2012* 58
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Edinburgh, 2012* 59
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2012* 60
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by William Beaumont Hospitals, 2012* 61
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Brigham and Women's Hospital, 2012* 62
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Leipzig, 2012* 63
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2012* 64
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Sheba Medical Center, 2012* 65
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Nebraska, 2012* 66
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Boston University, 2012* 67
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2012* 68
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Florida, 2012* 69
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2012* 70
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Cedars-Sinai Medical Center, 2012* 71
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Oxford, 2012* 72
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2012* 73
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2012* 74
Coronary Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Skejby Hospital, 2012* 75
List of Figures
Coronary Disease Therapeutics Market, Global, Clinical Trials by Zone (%), 2012* 8
Coronary Disease Therapeutics Market, Global, Clinical Trials by Top Countries, 2012* 9
Coronary Disease Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012* 10
Coronary Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2012* 11
Coronary Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2012* 12
Coronary Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2012* 13
Coronary Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2012* 14
Coronary Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2012* 15
Coronary Disease Therapeutics Clinical Trials, BRIC Countries (%), 2012* 16
Coronary Disease Therapeutics Clinical Trials, G7 Countries (%), 2012* 17
Coronary Disease Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012* 18
Coronary Disease Therapeutics Clinical Trials, E7 Countries (%), 2012* 19
Coronary Disease Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012* 20
Coronary Disease Global Clinical Trials Review, H1, 2012 (From Slideshare) Page 5/8
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Coronary Disease Therapeutics Market, Global, Clinical Trials by Phase (%), 2012* 21
Coronary Disease Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2012* 22
Coronary Disease Therapeutics Market, Global, Clinical Trials by Trial Status, 2012* 23
Coronary Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2006-2011 29
Coronary Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2012* 30
Coronary Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012* 32
Coronary Disease Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012* 34
GlobalData Methodology 101
Coronary Disease Global Clinical Trials Review, H1, 2012 (From Slideshare) Page 6/8
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Coronary Disease Global Clinical Trials Review, H1, 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 2 500.00 Quantity: _____
Site License--USD 5 000.00 Quantity: _____
Corporate License--USD 7 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Coronary Disease Global Clinical Trials Review, H1, 2012 (From Slideshare) Page 7/8
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Coronary Disease Global Clinical Trials Review, H1, 2012 (From Slideshare) Page 8/8